Sarepta Therapeutics Aktie
WKN DE: A1J1BH / ISIN: US8036071004
|
26.02.2025 22:15:42
|
Sarepta Therapeutics Q4 Profit Increases, But Misses Estimates
(RTTNews) - Sarepta Therapeutics (SRPT) announced a profit for its fourth quarter that increased from the same period last year but missed the Street estimates.
The company's bottom line totaled $159.0 million, or $1.50 per share. This compares with $45.7 million, or $0.47 per share, last year.
Excluding items, Sarepta Therapeutics reported adjusted earnings of $206.0 million or $1.90 per share for the period.
Analysts on average had expected the company to earn $2.06 per share. Analysts' estimates typically exclude special items.
The company's revenue for the period rose 65.9% to $658.4 million from $396.8 million last year.
Sarepta Therapeutics earnings at a glance (GAAP) :
-Earnings: $159.0 Mln. vs. $45.7 Mln. last year. -EPS: $1.50 vs. $0.47 last year. -Revenue: $658.4 Mln vs. $396.8 Mln last year.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Sarepta Therapeutics Inc.mehr Nachrichten
|
07:01 |
Ausblick: Sarepta Therapeutics stellt Zahlen zum jüngsten Quartal vor (finanzen.net) | |
|
05.08.25 |
Ausblick: Sarepta Therapeutics informiert über die jüngsten Quartalsergebnisse (finanzen.net) | |
|
16.06.25 |
Zweiter Todesfall bei Elevidys-Gentherapie: Sarepta-Aktie unter massivem Druck (finanzen.at) | |
|
16.06.25 |
MARKT USA/Wall Street vor fragiler Erholung (Dow Jones) | |
|
05.05.25 |
Ausblick: Sarepta Therapeutics vermeldet Zahlen zum jüngsten Quartal (finanzen.net) |
Analysen zu Sarepta Therapeutics Inc.mehr Analysen
Aktien in diesem Artikel
| Sarepta Therapeutics Inc. | 20,85 | 2,36% |
|